Basic Information
| LncRNA/CircRNA Name | PCAT6 |
| Synonyms | PCAT6, KDM5B-AS1, KDM5BAS1, PCAN-R1, ncRNA-a2, onco-lncRNA-96 |
| Region | GRCh38_1:202810954-202812156 |
| Ensemble | ENSG00000228288 |
| Refseq | NR_046325 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, RIP, Western blot, other |
| Sample | NSCLC tissues and cell lines (H1703, SK-MES-1 and H520) |
| Expression Pattern | up-regulated |
| Function Description | Loss-of-function and gain-of-function assays were used to assess the role of PCAT6 in promoting NSCLC progression. The results revealed that PCAT6 knockdown mitigated NSCLC cell growth by inducing G1-phase cell cycle arrest and apoptosis in vitro and in vivo. Whereas, PCAT6 overexpression could promoted tumor cell growth. Meanwhile, PCAT6 additionally promoted NSCLC cell migration and invasion. Furthermore, mechanistic investigation demonstrated that the oncogenic activity of PCAT6 is partially attributable to its repression of LATS2 via association with the epigenetic repressor EZH2 (Enhancer of zeste homolog 2). Overall, our study highlights the essential role of PCAT6 in NSCLC, suggesting that PCAT6 might be a potent therapeutic target for patients with NSCLC. |
| Pubmed ID | 30314898 |
| Year | 2018 |
| Title | Long Noncoding RNA PCAT6 Functions as an Oncogene by Binding to EZH2 and Suppressing LATS2 in Non-Small-Cell Lung Cancer |
External Links
| Links for PCAT6 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |